RIMA: a safe concept in the treatment of depression with moclobemide
Amrein, R.; Hetzel, W.; Stabl, M.; Schmid-Burgk, W.
Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 37(Suppl 1): 7-11
1992
ISSN/ISBN: 0706-7437 PMID: 1394030 Document Number: 390300
Moclobemide--a new, safer antidepressant drug--is described and clinical studies are reviewed. Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A. Unlike classical monoamine oxidase (MAO) inhibitors, moclobemide is devoid of hepatotoxicity and has only a slight potentiating effect on the hypertensive action of tyramine; treatment does not require a tyramine-restricted diet. Studies comparing moclobemide with tricyclic antidepressants (TCAs) indicate that moclobemide is significantly better tolerated than TCAs and slightly less well tolerated than placebo.